Bio- and Hemo-Compatible Silk Fibroin PEGylated Nanocarriers for 5-Fluorouracil Chemotherapy in Colorectal Cancer: In Vitro Studies
Authors:
- Ariana HudițăAriana Hudiță
- Ionuț Cristian RaduIRIonuț Cristian Radu
- Cătălin ZahariaCZCătălin Zaharia
- Andreea Cristina IonAIAndreea Cristina Ion
- Octav GinghinăOctav Ginghină
- Bianca GălățeanuBianca Gălățeanu
- Luminița MăruțescuLuminița Măruțescu
- Florin GramaFGFlorin Grama
- Aristidis TsatsakisAristidis Tsatsakis
- Leonid GurevichLGLeonid Gurevich
- Marieta CostacheMarieta Costache
Open Access
- 19 May 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (5) , 755
Abstract
5-fluorouracil (5-FU) remains the gold standard of treatment for colorectal cancer, but its poor bioavailability and high systemic toxicity highlight the urgent need for the development of novel delivery strategies to increase the efficacy of 5-FU treatment. The present study is aimed to design and validate a PEGylated Silk Fibroin Nanocarrier (SF/PEG nanoparticles (NPs)) as an efficient 5-FU delivery system for potential intravenous administration. Using the human adenocarcinoma HT–29 cell line as an in vitro model for colorectal cancer, the cytotoxicity screening of the SF/PEG NPs showed that pristine nanocarriers were highly biocompatible, while the addition of 5-FU triggers a dramatic reduction in tumor cell viability, proliferation potential and mitochondrial integrity as well as a significant increase in nitric oxide production. Despite their high in vitro cytotoxicity, the 5-FU SF/PEG NPs were found hemocompatible as no impact on red blood cells hemolysis or the phagocytic activity of the granulocytes was observed. Exposure of HT–29 tumor cells and blood samples to 5-FU SF/PEG NPs augmented the tumor necrosis factor-α levels. Moreover, 5-FU SF/PEG NPs showed an impact on tumor cell migration and invasive potential as both of these processes were inhibited by the NP treatment.Keywords
Funding Information
- Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii (PN-III-P1-1.1-PD-2016-1966–MagNaNoTer)
This publication has 52 references indexed in Scilit:
- Stealth Properties to Improve Therapeutic Efficacy of Drug NanocarriersJournal of Drug Delivery, 2013
- Targeted therapies in colorectal cancer—an integrative view by PPPMEPMA Journal, 2013
- Women's higher health risks in the obesogenic environment: a gender nutrition approach to metabolic dimorphism with predictive, preventive, and personalised medicineEPMA Journal, 2013
- The big picture on nanomedicine: the state of investigational and approved nanomedicine productsNanomedicine: Nanotechnology, Biology and Medicine, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Activation of Neutrophils by NanoparticlesThe Scientific World Journal, 2011
- Preclinical Studies To Understand Nanoparticle Interaction with the Immune System and Its Potential Effects on Nanoparticle BiodistributionMolecular Pharmaceutics, 2008
- New Approaches to the Adjuvant Therapy of Colon CancerThe Oncologist, 2006
- Tumor Necrosis Factor-α Generates Reactive Oxygen Species via a Cytosolic Phospholipase A2-linked CascadeJournal of Biological Chemistry, 2000
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989